IDH1 and neoplasm: Using an assay based on each patient’s individual tumor characteristics, Moulière et al. detected tumor-derived cfDNA in a cohort of IDH-wild type glioblastoma patients in CSF of 7/8 (88%) patients, in plasma of 10/12 (83%) patients, and in urine of 6/8 (75%) patients [86].